The ability of purified anaphylatoxins to induce human lung mast cell mediator release was investigated. In eight anti-IgE responsive (histamine release = 22±5%, mean±SEM) mast cell preparations of 1-96% purity, C5a and C5a des Arg (0.55 pg/ml to 55 pg/ml), failed to elicit or potentiate histamine release; lung fragments were similarly unresponsive. The related peptide C3a was also inactive. All anaphylatoxins failed to induce mast cell leukotriene C4 (LTC4) and prostaglandin D2 (PGD2) release. LTC4 release was also negligible from basophils where C5a was a potent histamine release stimulus. Supernatants from C5a-challenged mast cells remained fully active on basophils, excluding carboxypeptidase inactivation of C5a as an explanation for the lung mast cell results. In contrast to lung, skin mast cells were C5a-responsive (histamine release = 8±1%, at 55 gsg/ml, n = 2). We conclude that C5a, though devoid of activity on the human lung mast cell, is a human basophil and skin mast cell secretogogue. These findings demonstrate significant organ-specific heterogeneity in mast cell responsiveness.
Introduction
The biologically active fragment ofthe fifth complement component, C5a, is capable of triggering release reactions from diverse inflammatory cell types. These reactions result in increased vascular permeability, smooth muscle contraction, and an influx of inflammatory cells, especially neutrophils, that may cause end organ damage (1) . A major target organ for these protean effects is the lung (2) . Pathologically, dose-dependent lung destruction is characterized by the closure of arterioles and small airways, and disruption of the alveolar network (2) . In rodents and rabbits, direct intrabronchial instillation ofanaphylatoxins causes severe lung injury and acute respiratory distress (3, 4) . Removal of the COOH-terminal arginine of human C5a by serum carboxypeptidase-N results in formation ofC5a des Arg, nullifying its anaphylatoxiilproperties and diminishing its inflammatory effects (5, 6) .
Anaphylatoxins have long been suspected of playing a significant role in allergic disease. The effects of C5a as an in-characterizing the effects of anaphylatoxins in allergic lung reactions have been performed using animal models (11) (12) (13) (14) , and significant interspecies differences have been noted (1 1) . This study was undertaken to examine the ability of purified human C5a and C5a des Arg to directly induce histamine release from purified human lung mast cells, the central cell type of human asthma (15, 16) . We utilized highly purified, well characterized lipopolysaccharide-free (< 10 ng/ml) preparations of C5a and C5a des Arg to avoid misleading results from minor contaminants (17) .
We report that purified C5a, though a potent human basophil secretagogue and a weak human skin mast cell secretagogue, is devoid ofdirect anaphylatoxin activity for the human lung mast cell.
Methods
Materials. The following were purchased: elastase Type I, chymopa- (19, 20) . Briefly, lung specimens obtained at thorocotomy for bronchogenic carcinoma were finely minced and extensively washed in divalent cation-free Tyrode's buffer. Fragments were briefly incubated twice in a mixture of pronase (2 mg/ml) and chymopapain (0.5 mg/ml). Freed cells were harvested through Nytex nylon cloth (150Mgm pore size). Residual fiagments were further exposed to a mixture ofcollagenase (1 mg/ml) and porcine elastase (10 U/ml). All incubations and washes were performed at 220C; all recovered cells were immediately washed three times in large volumes of TGMD. Mast cell purities in these human lung cell suspensions ranged from 1 to 8% as determined by alcian blue staining (21) . In experiments requiring purified lung mast cells or designed to examine mast cell subpopulations separated on the basis ofdiameter, cell suspensions were subjected to counter-current elutriation, using previously reported methods (20) . Mast cells were purified (80-96%) by flotation of enriched elutriation fractions through a discontinuous Percoll gradient (22) .
Chopped human lung. The methods used to prepare and challenge human lung fragments have been reported in detail previously (23, 24) . Briefly, subpleural parenchymal strips well separated from tumor were carefully dissected free of visible blood vessels and pleura. Cut fragments of 10-20 mg each were washed six times in large volumes of Tyrode's buffer at 220C; fiagments were challenged within 1-2 h of lung resection.
Human skin mast cells. Mast cells were dispersed from human foreskin by the methods of Benyon et al. (25) . Briefly, skin fragments were finely minced and extensively washed in divalent cation-free Tyrode's buffer. Fragments were exposed to collagenase (1.5 mg/ml) and hyaluronidase (0.5 mg/ml). Dispersed cells were harvested through Nytex cloth and washed with RPMI/1.5% fetal calf serum. Mast cell purities ranged from 1 to 3%.
CSa, C3a, and C5a des Arg. C5a and C3a were purified from human serum as previously described (17) . The C5a preparation used for these experiments contained 55 Mg protein/ml and had 1 X 106 U/ml of myeloperoxidase-releasing activity when tested with cytochalasin B-treated human neutrophils (26) . Both the C3a and C5a were positive when tested for their ability to cause increased vascular permeability in guinea pig skin (5 the maximum amounts of each that could be generated from activation of serum complement: C3 1 mg/ml, C3a from 100% C3 conversion 60 mg/ml; C5 50-100 g/ml, C5a from 100% conversion 3-6 g/ml. In chopped lung studies, six 10-20 mg fragments in 0.5-1.0 ml were similarly challenged in TGMDCM. After 45 min for basophil incubations (7, 8, 18) or 20 min for mast cell incubations (19) , cells were rapidly pelleted and supernatants removed for analysis of mediator release. In chopped lung studies, one-half ofthe supernatant was removed for histamine, LTC4 and PGD2 analysis and the volume was replaced with 4% perchloric acid.
In the experiments indicated, basophils, mast cells, or chopped lung preparations were pretreated with cytochalasin B (1 Mg/ml) for 5 min before addition of C5a or C5a des Arg. Histamine released into the supernatant was expressed as the net histamine released divided by the total histamine content X 100%. The total cellular histamine content was determined by cell lysis in 2% perchloric acid. The total histamine content of lung fragments was determined by boiling the perchloric acid-treated fragments for 10 min. Spontaneous histamine release was always < 5% of cellular histamine. Histamine measurements were performed by the automated spectrofluorometric method of Technicon Co. (Tarrytown, NY). Variation between replicates was consistently < 5%. All experiments were performed on at least three individual basophil and mast cell donors.
LTC4. LTC4 measurements were performed on unextracted mast cell or lung fragment supernatants using the radioimmunoassay previously described (27). Though the antibody shows 50% cross-reactivity with leukotriene D4 (LTD4), the LTC4 generated by isolated mast cells under these experimental conditions is not further metabolized (28) . The assay is sensitive to 0.1 ng/ml of LTC4.
Prostaglandin D2 (PGD2). PGD2 measurements were similarly performed on unextracted supernatants. The antibody has < 0.5% crossreactivity with PGF2a PGE, TxB2 and 6-keto-PGF1, (29). This assay is sensitive to 0.1 ng/ml of PGD2. Statistics. Data were expressed as the mean±SEM in the text and figures. Multiple comparisons were performed using an analysis of variance (ANOVA) and a Newman-Keul test. Significance in all tests was taken at P < 0.05.
Results
Anaphylatoxin challenge ofhuman lung mast cells. Mast cells from eight different lungs were challenged with release stimuli (Fig. 1) . In the first four experiments, mast cells at 80, 92, 93, and 96% purity were challenged for 20 min at 370C with varying doses of anti-IgE (0.1-30 ,g/ml) and C5a and C5a des Arg anaphylatoxins (0.55 pg/ml to 55 Atg/ml). Anaphylatoxin, but not anti-IgE, challenges were performed in the presence of cytochalasin B (1 ug/ml). In all four experiments, purified mast cells responded to anti-IgE (peak release of 23±5%, mean±SEM) but failed to respond to anaphylatoxins at any dose. In four additional human lung experiments we examined the possibility that mast cells needed "helper" cell types to respond. Lung cell suspensions containing 1, 4, 6, and 8% mast cells were similarly challenged. Again, anaphylatoxin failed to elicit histamine release, while anti-IgE proved an effective stimulus (peak release = 21±7%).
Because of a prior report showing a loss ofbasophil responsiveness to complement if cells were exposed to 37°C before challenge (7), lung cells were constantly kept at 25°C until 25 and four purified mast cell experiments were identical they were combined above. Anti-IgE results represent the peak histamine release response (mean±SEM) from dose-response curves.
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Despite the failure to exert a direct mast cell release effect, we investigated the potential for anaphylatoxins to potentiate an anti-IgE challenge in the absence and presence of cytochalasin B (1 ug/ml). As shown in Fig. 2, no tional correlates (32) . We therefore examined functionally distinct human lung mast cell subpopulations, separated on the basis of their diameters by elutriation (20) , for selective responses to release stimuli (Fig. 3) . As (Fig. 4) (histamine release = 17±5%) resulted in LTC4 release of 6.1±3.3 ng/g wet wt and PGD2 release of 135±3.5 ng/g wet wt of lung. Interestingly, even though the anaphylatoxins are potent stimulators of basophil histamine release, they failed to activate pathways of LTC4 generation. After challenges of three highly responsive basophil donors with C5a (maximum histamine release = 48±4% at 5.5 ,ug/ml, ECQ, = 0.9 Ag/ml) and with C5a des Arg (maximum histamine release = 26±4% at 55 ,g/ml, EC50 = 10.7 Mg/ml) LTC4 was undetectable in the supernatants. This contrasts with anti-IgE-induced (0.3 ,ug/ml) release: histamine release of 57±6.0% was coupled with appreciable LTC4 release of 2.4±0.7 fg/basophil. Human skin mast cells. The impotence of C5a as a lung mast cell secretagogue contrasted strikingly with prior in vivo studies where injection of C5a into human skin produced wheal and flare responses and resulted in mast cell degranulation as visualized both at the light and electron microscopic level (33, 34) . To evaluate potential human organ-specific differences in reactivity, mast cells dispersed from human foreskin were challenged with GOa, C5a des Arg, and ionophore A23187 (0.3 ,g/ml). In two experiments, C5a induced 8±1% histamine release at 55 ,g/ml, 6±1% at 5.5 Ag/ml and 0% at 0.55 ,gg/ml. At the same concentrations, C5a des Arg failed to elicit release. lonophore-induced release was 28±4%. In a third experiment, minced skin fragments were challenged; C5a induced 4% histamine release, C5a des Arg 0% release and ionophore 6% histamine release. The limitations in specimen size did not allow for arachidonate metabolite measurements in the skin samples. A critical role for the anaphylatoxins C5a and C5a des Arg has been suggested in both immunologic and nonimmunologic lung disease (1) (2) (3) (4) (11) (12) (13) (14) . In fact, the lung may serve as the major target organ for the effects ofthese mediators (1 1). Studies undertaken to identify the nature of the mediators released during anaphylatoxin-induced lung injury have found products derived from degranulated mast cells, the central cell type of allergic asthma (1 1, 12 ). These studies also emphasized the significant species differences among the specific activities of the anaphylatoxins themselves. For this reason, a study was undertaken to define the actions ofpurified human C5a and its putative physiologic form C5a des Arg (20) . We felt that direct C5a challenge of quantitatively small subsets might magnify and define effects that are lost in whole lung fragments or in whole lung suspensions. Again, under these conditions, we failed to find a C5a responder subset.
Discussion
The failure of human lung mast cells to respond to C5a obviously contrasts with older human skin studies (33, 34) . In those studies, injection of anaphylatoxins produced wheal and flare responses that were ascribed to cutaneous mast cell degranulation; reactions were partially inhibitable if skin sites were pretreated with an antihistamine (33, 34) . One obvious explanation for these differences is that of organ-specific differences in mast cell type and function (lung vs. skin). Studies in rodents have clearly demonstrated marked differences in structure and function between mast cells in the peritonium (connective tissue mast cells) and gastrointestinal mucosa (mucosal mast cells) (35). Even within organs, (e.g., rat skin), there is histochemical evidence of two mast cell subtypes (36) . To test the hypothesis that C5a responsiveness was organ specific, we challenged both skin mast cell suspensions (two experiments) and minced fragments (one experiment) with C5a and C5a des Arg. In each instance, low level (4-9%) histamine release resulted. This in vitro data is consistent with the intradermal injection studies. Since human skin reactivity to C5a (and C3a) are only partially inhibitable with antihistamines, it is possible that the observed wheal and flare responses are heavily dependent on the direct stimulation of cells other than mast cells. In fact, this has been shown in rabbits where the skin reactivity of intradermally administered C5a is independent of histamine release (37): the observed plasma exudation and edema appears to involve a synergism between complement fragments and vasodilator prostaglandins (e.g., PGE2) derived from non-mast cell sources (37). Another alternative explanation is that target cells (e.g., neutrophils), directly stimulated by C5a, may release their own vasoactive mediators and/or secondarily stimulate secretion of mast cell/basophil mediators. For example, C5a can stimulate neutrophil generation and release of the labile arachidonate intermediate leukotriene A4 (LTA4) (38) ; released LTA4 may then be "remodelled" by mast cells and other cells to generate bioactive arachidonate products (38) . Though this hypothesis is attractive, our results cast doubt that the C5a response is dependent on neutrophils. C5a challenges of whole lung suspension (5% neutrophils) and of mixed leukocyte preparations (50-70% neutrophils) failed to stimulate LTC4 release. This result was particularly surprising in the mixed leukocyte preparation, where C5a proved as effective a histamine liberator as anti-IgE, but was an insufficient signal to activate basophil arachidonate metabolism. Platelet-activating factor (PAF), a mediator capable of contributing to wheal and flare reactions, is directly released from neutrophils following anaphylatoxin challenge (39, 40) , and may prove an important contributor to the skin responses.
In conclusion, purified C5a is a potent stimulant of the circulating basophil, a much weaker stimulant of the human cutaneous mast cell, and is devoid of activity on the human lung mast cell. These results point to a major difference in the biology of these related cell types (16) . Our studies also suggest that significant differences exist in responsiveness to complement fragments among lung mast cells of human and animal origins.
